研究单位：[1]Clinical professor, Tongji Hospital[2]Tongji Hospital华中科技大学同济医学院附属同济医院[3]Hubei Xinhua Hospital[4]Wuhan No.1 Hospital[5]Wuhan Central Hospital
研究目的：
Some patients infected with the COVID-19 can develop uncontrolled immune response, leading to potentially life-threatening damage to lung tissue. Tocilizumab was first approved by the U.S. FDA in 2010 for rheumatoid arthritis and might now be used to treat serious COVID-19 patients with lung damage, according to China's National Health Commission updated its treatment guidelines in 7th version.Continuous Renal Replacement Therapy (CRRT) was recommended by China's National Health Commission treatment guidelines in 1st-7th version to control sever COVID-19 patients.
